Navigation Links
New Study Confirms Role for Pertussis Immunization of Entire Family,in Reducing Infant Pertussis

Majority of Infants Infected by Members of Their Own Household

SWIFTWATER, Pa., March 27, 2007 /PRNewswire/ -- A new study released today in the April issue of The Pediatric Infectious Disease Journal about the transmission of pertussis -- commonly known as whooping cough -- found that household members were the source for 71 to 82 percent of cases among infants for whom a source case could be identified.(1) The study demonstrates the importance of vaccination of close contacts of infants to reduce the number of infant pertussis cases and potentially save lives.(1,2)

The study, the first simultaneous evaluation of infant pertussis conducted in four countries [including the United States], was led by researchers at the University of North Carolina, Chapel Hill (UNC-CH) and was supported by sanofi pasteur, the vaccines business of the sanofi-aventis Group. This study was conducted over a 20-month period and found that, among infants with pertussis for whom the source could be identified, parents were the source of 55 percent of cases, followed by siblings (16 percent), aunts/uncles (10 percent), friends/cousins (10 percent), grandparents (6 percent), and part-time caregivers (2 percent).(1) In previous studies, identifying the source of infection was hindered by incomplete case data and less comprehensive laboratory evaluation of contacts.

Pertussis is a highly contagious bacterial infection. The disease is spread though airborne droplets that are transmitted when an infected person coughs or sneezes. It may start with symptoms similar to a mild cold or a dry cough that persists and eventually worsens. The infected person may look and feel healthy between episodes of coughing. If left untreated, pertussis can be spread for several weeks. At particular risk are newborns who have not been vaccinated or fully vaccinated against the disease.(3) They are more vulnerable to severe pertussis and face the p
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/21/2008)... Aug. 21 /-,Bayer HealthCar...Inc.,(Nasdaq: ONXX ) today announced the companie...enib as Adjuvant Treatment in the Prevention of,Re...ndomized, double-blind,placebo-controlled Phase 3...s as adjuvant treatment, which is treatment follow...
(Date:8/20/2008)...nobia Pharma, an emerging biotech,company focused ...disorders, today announced that the first patient ...een dosed. Enobia is investigating Enzyme,Replacem...of this rare and,often crippling genetic bone diso...nder two separate protocols, ENB-0040 will be eval...
(Date:8/19/2008)...-,Pharmaceutical company Ph...hat the Phase 3 clinical trial evaluating the long...iectasis has concluded with no serious,adverse eve...treatment., A total of 123 subjects started treat...ubjects completed the full 12 months of the trial....
(Date:8/19/2008)...be used to identify molecular,signature of motor n...ire-USNewswire/ -- ALS Therapy,Development Institu...n ALS,biomarker effort using blood samples collect...ships. These ongoing projects are part of the,Inst...expression of genes,and proteins, at the onset of,...
Breaking Medicine Technology:Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 2Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 3Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 4Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 5Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 312 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 212 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 3ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Researchers discover natural herbicide released by grass 1144 1Researchers discover natural herbicide released by grass 1144 2St Jude program reduces weight gain in young African American girls 5856 1St Jude program reduces weight gain in young African American girls 5856 2Skin Cancer Prevention Update 3A 5853 1Skin Cancer Prevention Update 3A 5853 2Skin Cancer Prevention Update 3A 5853 3Skin Cancer Prevention Update 3A 5853 4Skin Cancer Prevention Update 3A 5853 5Feeling Stressed 3F 5850 1Feeling Stressed 3F 5850 2Feeling Stressed 3F 5850 3Feeling Stressed 3F 5850 4
...ased Enzyme Levels in Two Most Common Mutations, C...us,Therapeutics, a biopharmaceutical company devel...logical chaperones for the,treatment of a range of...ill present the results of preclinical studies of,...cher disease at,the of Medical Genetics (ACMG) ann...
...clinical Studies Presented at the Targeted,Antican... Molecular,Targets for Cancer Meetings Support Pha...rch 20, 2007,/PRNewswire-FirstCall/ -- Sunesis Pha...n its development-stage compound, SNS-314, at,two ...ticancer,medicines. Findings from in vitro and in ...
Other Medicine Technology:Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 2Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 3
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...ing system for use by physicians predicts early ri...ransient ischemic attack, known as TIA and also ca...out 240,000 TIAs are diagnosed every year in the U...United Kingdom. A TIA is a serious condition cause...
...nase (ADH) is one of the major enzymes involved in...phic at two loci, ADH1B and ADH1C.// The three al...ed with protection from alcohol dependence, a new ...tionship between the ADH1B*3 allele and alcohol-re...
...global acquisitions last year, India's Ranbaxy Lab...the generic drugs business of German// pharmaceuti...llion. ‘We are in talks with private equity funds... executive Malvinder Singh said on the margins of ...
...ochrane Review concluded antidepressants bupropion...es //of giving up smoking and have few side-effect...RIs) such as fluoxetine (Prozac) are not effective...own to help people quit smoking, not everyone is h...
Other Medicine News:Health News:New Tool Improves Prediction of Stroke Risk 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 3
The QIAamp Viral RNA Mini Kit allows purification of viral nucleic acids from cell-free fluid samples. Examples of viral nucleic acids that can be isolated with this kit include, but are not limited
The PersonalLAB junior is an automated microplate analyzer capable of fully automating immunoenzymatic techniques using a microplate format, per the reagent manufacturer's instruction for use and spe
MAP D-Type can combine a number of assay steps for up to 180 microplates on a simple to use benchtop device. The D-Type base instrument is a multifunctional stand-alone device but also provides easy
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi
Medicine Products: